Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages 2362-2369

  Tuvia, S ^a   Atsmon, J ^b   Teichman, S L ^a   Katz, S ^a   Salama, P ^a   Pelled, D ^a   Landau, I ^a   Karmeli, I ^a   Bidlingmaier, M ^c   Strasburger, C J ^d   Kleinberg, D L ^e   Melmed, S ^f   Mamluk, Roni ^a  

^a Chiasma   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOLIN; OCTREOTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; FECES; FEMALE; FOOD DRUG INTERACTION; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFUSIONS, PARENTERAL; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; RESEARCH SUBJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863588864     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1179     Document Type: Article

References (32)

1. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140
2. Melmed S 2009 Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202
3. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254 (Pubitemid 26030676)
4. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392 (Pubitemid 27500164)
5. Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A 2007 A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 102:1397-1405 (Pubitemid 46976298)
6. Sonnenberg GE, Keller U, Perruchoud A, Burckhardt D, Gyr K 1981 Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 80:526-532 (Pubitemid 11183954)
7. Chanson P, Timsit J, Harris AG 1993 Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25:375-391 (Pubitemid 23327923)
8. Fricker G, Bruns C, Munzer J, Briner U, Albert R, Kissel T, Vonderscher J 1991 Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. Gastroenterology 100:1544-1552
9. Fricker G, Fahr A, Beglinger C, Kissel T, Reiter G, Drewe J 1996 Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations. Br J Pharmacol 117:217-223 (Pubitemid 26030270)
10. Fuessl HS, Domin J, Bloom SR 1987 Oral absorption of the somatostatin analogue SMS 201-995: theoretical and practical implications. Clin Sci (Lond) 72:255-257 (Pubitemid 17231153)
11. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S 2011 Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:284-294
12. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 80:2768-2775
13. Dorkoosh FA, Verhoef JC, Verheijden JH, Rafiee-Tehrani M, Borchard G, Junginger HE 2002 Peroral absorption of octreotide in pigs formulated in delivery systems on the basis of superporous hydrogel polymers. Pharm Res 19:1532-1536 (Pubitemid 35266559)
14. Drewe J, Fricker G, Vonderscher J, Beglinger C 1993 Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br J Pharmacol 108:298-303 (Pubitemid 23032529)
15. Thanou M, Verhoef JC, Marbach P, Junginger HE 2000 Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 89:951-957
16. Thanou M, Verhoef JC, Verheijden JH, Junginger HE 2001 Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs. Pharm Res 18:823-828 (Pubitemid 32783519)
17. Tuvia S, Salama P, Weinstein I, Marom K, Neumark E, Arama ML, Mishli N, Levy S, Lapidot T, Kadoshi R, Katz S, Judelman A, Mamluk R 2010 Octreolin a safe oral alternative for parenteral octreotide treatment. Growth Horm IGF Res 20(Suppl 1):S35-S36
18. Cano-Cebrián MJ, Zornoza T, Granero L, Polache A 2005 Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2:9-22 (Pubitemid 40590917)
19. Prescribing information 2010 Sandostatin injection. East Hanover, NJ; Novartis Pharmaceuticals Corporation
20. Weinstein I, Tzabari M, Salama P, Mamluk R, Marom K 2010 Pharmaceutical compositions and related methods of delivery. PCT International Patent Application WO 2010/ 032140:122
21. Growth Hormone Research Society 2000 Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 85:3990-3993
22. Ho KK 2007 Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157:695-700
23. Müller A, Scholz M, Blankenstein O, Binder G, Pfäffle R, Körner A, Kiess W, Heider A, Bidlingmaier M, Thiery J, Kratzsch J 2011 Harmonization of growth hormone measurements with different immunoassays by data adjustment. Clin Chem Lab Med 49:1135-1142
24. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP 1981 Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 67:1361-1369 (Pubitemid 11099350)
25. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
26. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ 2009 Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69:2207-2226
27. Köhler E, Duberow-Drewe M, Drewe J, Ribes G, Loubatiéres- Mariani MM, Mazer N, Gyr K, Beglinger C 1987 Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. Eur J Clin Pharmacol 33:167-171 (Pubitemid 17149230)
28. Damgé C, Vonderscher J, Marbach P, Pinget M 1997 Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J Pharm Pharmacol 49:949-954 (Pubitemid 27478385)
29. Maggio ET, Grasso P 2011 Oral delivery of octreotide acetate in Intravail improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul Pept 167:233-238
30. Aoyagi N, Ogata H, Kaniwa N, Uchiyama M, Yasuda Y, Tanioka Y 1992 Gastric emptying of tablets and granules in humans, dogs, pigs, and stomach-emptying-controlled rabbits. J Pharm Sci 81:1170-1174 (Pubitemid 23018121)
31. Lennernäs H 2007 Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8:645-657 (Pubitemid 47578114)
32. Sherlock M, Woods C, Sheppard MC 2011 Medical therapy in acromegaly. Nat Rev Endocrinol 7:291-300